Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 10/06 04:01:56 pm
93.42 USD   -1.41%
10:18a UNITEDHEALTH : Dow Movers: UNH, DD
10/04 JOHNSON & JOHNS : Announces Completion of Cordis Divestiture to Card..
09/29 S&P 500 bounces back after nearing August low
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : J&J Cancer Drug Zytiga Now Backed For Publicly Funded Use In UK

05/16/2012 | 05:11am US/Eastern

The U.K.'s health-care cost-effectiveness regulator Wednesday reversed an earlier decision and approved the publicly funded use of Johnson & Johnson's (JNJ) prostate-cancer pill Zytiga, after the U.S. company cut its price further.

Also known as abiraterone, Zytiga removes the prostate cancer tumor's supply of testosterone, preventing it from growing further and potentially extending a patient's life by more than three months. The medicine was rejected for use in the U.K. in February on grounds its terms of use wouldn't offer value for money.

Andrew Dillon, chief executive of the U.K.'s National Institute for Health and Clinical Excellence, or NICE, Wednesday said the manufacturer subsequently submitted fresh information, including a revised patient access scheme containing a deeper price discount to the National Health Service and more information about which patients would most benefit from its use and how many patients could receive the drug.

"These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS," Dillon said in a statement. "It is an effective treatment, potentially extending life by more than three months, and it also allows patients to be treated at home as it can be taken orally."

Abiraterone costs GBP2,930 for a 30-day supply of 120 tablets. NICE didn't specify the size of the price cut offered by Johnson & Johnson.

Zytiga was approved by U.S. and European drug regulators last year. It is set to generate peak-year sales of $910 million.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

React to this article
Latest news on JOHNSON & JOHNSON
10:18a UNITEDHEALTH : Dow Movers: UNH, DD
10/05 JOHNSON & JOHNSON : Mrs Saraki urges increased access to skilled midwives
10/04 JOHNSON & JOHNSON : Announces Completion of Cordis Divestiture to Cardinal Healt..
09/30 JOHNSON & JOHNSON : Mrs Saraki urges increased access to skilled midwives
09/30 JOHNSON & JOHNSON : Global Wellness Summit Announces 9th Annual Conference Highl..
09/29 S&P 500 bounces back after nearing August low
09/29 DOW MOVERS : Gs, mcd
09/28 PHENOTYPIC ASSAYS - A NEW AGE OF MOD : 15 Progressive Insights from Novartis, As..
09/27 JOHNSON & JOHNSON : Randy Alcorn: Volkswagen, Johnson & Johnson, and Confronting..
09/25 JOHNSON & JOHNSON : The Miami Herald Fred Grimm column
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Income Statement Evolution
More Financials